Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/57645
Title: | Neoadjuvant and adjuvant systemic treatment for hepatocellular carcinoma |
Authors: | MATHIAS-MACHADO, Maria Cecilia; FONSECA, Leonardo G. da |
Citation: | HEPATOMA RESEARCH, v.7, article ID 67, 12p, 2021 |
Abstract: | Hepatocellular carcinoma (HCC) is a highly lethal malignancy, and few patients are candidates for curative-intended therapies. The mainstay of curative treatment in HCC is surgical resection, ablation, and transplantation. However, rates of recurrence are high, and there is no established approach to reduce the risk of recurrence and mortality. We discuss the available data and current landscape of (neo)adjuvant therapies aimed at decreasing recurrence risk and improving overall survival, including liver-directed therapies, tyrosine kinase inhibitors, and immunotherapy. Neoadjuvant strategies aimed at downstaging advanced HCC to enable local treatment and minimize the risk of recurrence using novel agents are also a topic of interest in current research. The improvements achieved in the advanced stages with immune-checkpoint inhibitors are priming ongoing trials that address potential future directions for both adjuvant and neoadjuvant strategies that may change the treatment paradigm of HCC in the near future. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - LIM/07 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_MATHIAS-MACHADO_Neoadjuvant_and_adjuvant_systemic_treatment_for_hepatocellular_carcinoma_2021.PDF | publishedVersion (English) | 395.94 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.